New research reveals that high-fat foods rapidly disable critical immune cells that protect your intestinal barrier in a ...

po.cwru.edu Background: The CD40/CD40L system, a key regulator and amplifier of immune reactivity, is activated in inflammatory bowel disease (IBD ... Surface CD40L expression level was measured by ...

This report describes the development and validation of a cellular, immunofluorescence-based flow cytometry assay that ... according to the stage of the disease. This finding is in agreement ...

To support physicians in treating cancer patients, oncology laboratories can benefit from adopting end-to-end automation of flow cytometry workflows. Rapid advances in automation are improving ...

Once submitted, we will try and place you in contact with a suitable Flow Cytometry Systems supplier within 48 hours.

Fluorescence-activated flow cytometry ... against infectious diseases. Although the identification of such correlates might not require more than six- to eight-colour flow cytometry, the process ...

will shed light on this specific disease form. Antoine Pacheco, Platform Manager for Clinical Instrumentation at Beckman Coulter, will conduct another session from the laboratory, demonstrating the ...

Sabina Ali, MD Starting this summer, UCSF Benioff Children’s will be one of only a handful of children’s hospitals on the West Coast to offer intestinal ultrasound to children with inflammatory bowel ...

Crohn's disease is a chronic inflammatory bowel disease (IBD) that affects the digestive tract, often causing abdominal pain, persistent diarrhea, rectal bleeding, weight loss, and fatigue during ...

Medscape Medical News, May 21, 2025 Alert MHRA Approves Guselkumab for Inflammatory Bowel Disease The MHRA has approved guselkumab to treat Crohn’s disease and ulcerative colitis in adults who ...

The British Society of Gastroenterology (BSG) has published new guidelines on colorectal cancer surveillance for patients with inflammatory bowel disease (IBD). Published in the BMJ journal Gut ...

Werewolf’s findings are summarized in a poster titled, “Development of WTX-921, A Conditionally Active IL-10 INDUKINE TM Molecule for the Treatment of Inflammatory Bowel Disease” (Board #1230).